SHYNDEC(SH:600420)2018-04-17 16:00Financial Performance - Operating revenue rose by 31.36% to CNY 3,109,236,551.88 year-on-year[6] - Net profit attributable to shareholders increased by 8.64% to CNY 173,325,640.76 compared to the same period last year[6] - Basic and diluted earnings per share rose by 8.70% to CNY 0.1562[6] - The total profit for the current period was ¥312,880,410.41, slightly up from ¥311,175,933.73, reflecting a marginal increase of about 0.5%[27] - Net profit for the current period was ¥258,631,262.02, compared to ¥248,856,782.30 in the previous period, reflecting an increase of approximately 3.1%[27] - The net profit attributable to shareholders of the parent company was ¥173,325,640.76, up from ¥159,546,917.21, indicating a growth of around 8.3%[28] Cash Flow - Cash flow from operating activities improved significantly to CNY 247,783,653.05, a turnaround from a negative cash flow of CNY -2,183,792.98 in the previous year[6] - The company reported a significant increase in cash flow from operating activities, indicating improved operational efficiency[6] - Cash inflow from operating activities increased to $2,134,696,092.03, up from $1,675,206,921.48, representing a growth of approximately 27.4% year-over-year[33] - Net cash flow from operating activities turned positive at $247,783,653.05, compared to a negative cash flow of $2,183,792.98 in the previous period[33] - Total cash outflow for operating activities was $92,966,111.10, down from $188,667,462.39, indicating improved cost management[37] Assets and Liabilities - Total assets increased by 5.30% to CNY 15,975,286,050.58 compared to the end of the previous year[6] - Total current assets amounted to ¥7,766,227,114.96, up from ¥6,919,923,607.58 at the beginning of the year[18] - Current liabilities rose to CNY 6,014,044,653.38, up from CNY 5,390,426,266.96, reflecting an increase of approximately 11.6%[20] - Total liabilities reached CNY 8,068,881,035.02, compared to CNY 7,522,817,294.22, an increase of around 7.3%[20] - Owner's equity increased to CNY 7,906,405,015.56 from CNY 7,647,773,753.54, showing a growth of about 3.4%[20] Shareholder Information - The total number of shareholders reached 25,934 at the end of the reporting period[11] - The largest shareholder, Shanghai Pharmaceutical Industry Research Institute, holds 21.58% of the shares[11] Income and Expenses - Non-operating income totaled CNY 5,078,168.82, primarily from government subsidies and asset disposals[9] - Sales expenses surged by 175.93% to ¥834,618,046.18 from ¥302,476,984.69, attributed to increased marketing efforts and channel costs[15] - Investment income increased by 91.47% to ¥6,479,474.20 from ¥3,384,127.81, reflecting higher returns from joint ventures[15] - The company reported a decrease in income tax expenses to ¥54,249,148.39 from ¥62,319,151.43, a reduction of approximately 12.5%[27] - Other income for the current period was ¥9,181,612.03, compared to ¥5,262,506.29 in the previous period, indicating an increase of about 74.5%[27] Investments and Financing - The company plans to issue convertible bonds totaling up to ¥20.35 billion, pending regulatory approval[16] - Cash outflow for investing activities totaled $282,939,451.35, significantly higher than $86,013,759.26 in the prior period, indicating increased investment activity[37] - Net cash flow from investing activities was negative at -$267,932,051.35, compared to -$86,012,579.26 previously, reflecting higher capital expenditures[37] - Cash inflow from financing activities was $50,000,000.00, with cash outflow totaling $61,448,203.01, resulting in a net cash flow of -$11,448,203.01 for financing activities[37]